Physician profile
Stephanie E Fox
NPI 1932977352
$602.31
in general payments reported to CMS, 2019-2025
13 companies · $559 in 2025
The $559 reported for 2025 was more than what 78% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $43.37 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $184.43 | 2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $106.24 | 2024-2025 | |
| Pfizer INC. | $56.49 | 2025 | |
| Amgen INC. | $47.17 | 2025 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $39.79 | 2025 | Spravato |
| Lilly USA, LLC | $31.97 | 2025 | Zepbound |
| Verona Pharma, INC. | $24.07 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $23.80 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $22.75 | 2025 | Korlym |
| Eisai INC. | $19.79 | 2025 | |
| Heron Therapeutics, INC. | $19.09 | 2025 | Zynrelef |
| Astrazeneca Pharmaceuticals LP | $13.66 | 2025 | Airsupra |
| Phathom Pharmaceuticals, INC. | $13.06 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.